Rx Prescripttion Only-YMYL Medical Content

Abiraxen 250 mg

Abiraterone Acetate 250mg tablets –

Approved, in combination with prednisone, for adult men with metastatic castration-resistant prostate cancer (mCRPC) — both pre- and post-docetaxel settings — and for metastatic high-risk castration-sensitive prostate cancer (mCSPC), always used alongside androgen deprivation therapy (ADT).

15.8 mo

Median OS in post-docetaxel mCRPC vs 11.2 mo placebo (COU-AA-301)

Not reached

Median OS in high-risk mCSPC vs 34.7 mo placebo (LATITUDE) — 38% mortality reduction

16.5 mo

Median rPFS in chemo-naïve mCRPC vs 8.3 mo placebo (COU-AA-302)

CYP17

Blocks androgen biosynthesis at all three sites — testes, adrenal glands, and tumor itself

Confirm prostate cancer stage and castration status

Must be used alongside ADT (GnRH agonist/antagonist or prior orchiectomy). For mCRPC — disease progressing despite castrate testosterone levels. For high-risk mCSPC — metastatic disease with high-risk features (Gleason ≥8, ≥3 bone lesions, or visceral metastases).

Confirm prednisone co-prescription and endocrine plan

Abiraterone must always be combined with prednisone (5mg twice daily for mCRPC; 5mg once daily for mCSPC) — the corticosteroid is required to prevent mineralocorticoid excess from CYP17 inhibition. Never take abiraterone without it.

Assess baseline liver function and cardiovascular status

Liver function tests required before starting and monitored throughout; hypertension, hypokalemia, and fluid retention from mineralocorticoid excess require cardiovascular baseline assessment, especially in patients with pre-existing heart disease.

Discuss the empty stomach requirement and food interaction

Abiraterone exposure increases dramatically when taken with food — systemic exposure can increase up to 10-fold with a high-fat meal versus fasted state. Must be taken at least 1 hour before or 2 hours after any food, without exception.

Important safety information: Abiraterone inhibits CYP17, causing a secondary rise in mineralocorticoids that can lead to hypertension, hypokalemia (low potassium), and fluid retention — requiring monthly monitoring of blood pressure, serum potassium, and fluid balance. Hepatotoxicity, including severe and fatal liver injury, has been reported and requires liver function monitoring. Abiraterone is absolutely contraindicated in women who are or may become pregnant (Pregnancy Category X).

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Abiraterone fundamentally changed prostate cancer treatment — it showed for the first time that blocking androgen synthesis beyond castration provides a meaningful survival benefit. The food interaction is critical and consistently under-discussed: taking this with food can increase drug exposure dramatically and unpredictably, which affects both efficacy and side effects. The prednisone requirement is non-negotiable — stopping it abruptly risks adrenal crisis.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my oncologist about starting abiraterone acetate?

Here are key questions to bring to your oncologist — the prednisone co-prescription, the food interaction, and the mineralocorticoid monitoring plan are the three areas most distinctive to abiraterone and worth establishing clearly before the first dose.

Before confirming abiraterone as your treatment

Which stage of prostate cancer am I being treated for — metastatic castration-resistant (mCRPC) or metastatic high-risk castration-sensitive (mCSPC)?
Am I already on androgen deprivation therapy (ADT), and will that continue alongside abiraterone?
Have I received prior docetaxel chemotherapy, and does that affect which treatment setting abiraterone is being used in?
Why is abiraterone being recommended over enzalutamide or another androgen receptor pathway inhibitor at this point?
Are there clinical trials I should know about?

About the prednisone requirement — the most distinctive feature of this drug

What exact prednisone dose will I be taking — 5mg twice daily (mCRPC) or 5mg once daily (mCSPC)?
What happens if I miss a prednisone dose — is it safe to skip it, or should I take it as soon as I remember?
Can I ever stop the prednisone if I feel unwell — and if not, why not? (Stopping abruptly risks adrenal insufficiency.)
Who prescribes and manages the prednisone — my oncologist, primary care doctor, or both?
Are there situations where the prednisone dose would need to be increased temporarily — for example, during illness, surgery, or significant physical stress?
What are the signs of adrenal insufficiency — severe weakness, dizziness, low blood pressure, confusion — that require emergency care?

About the food and timing requirement

What does “empty stomach” mean in exact practical terms — how long before or after any food must I take abiraterone?
Does “food” include drinks other than water — coffee, juice, milk?
What happens if I accidentally take it with a meal — is this a safety concern or just an efficacy issue?
What is the best time of day to build this into my routine given I take it four tablets at once?

About mineralocorticoid effects — hypertension, potassium, and fluid retention

Will my blood pressure, serum potassium, and fluid balance be monitored monthly as recommended?
Do I have a home blood pressure monitor, and what reading should prompt me to call?
What symptoms of low potassium — muscle cramps, weakness, irregular heartbeat — should prompt an urgent check?
What symptoms of fluid retention — swollen ankles, sudden weight gain, breathlessness — warrant attention?
Do I have any history of heart disease, arrhythmia, or hypertension that changes how closely these need to be managed?

About liver monitoring

Will baseline liver function tests be done before starting, and how often will they be repeated?
What liver symptoms — yellowing of skin or eyes, dark urine, severe right-sided abdominal pain — should prompt an urgent call?
Do I have any pre-existing liver condition that affects my starting dose or monitoring plan?

About dosing and administration

The standard dose is 1,000mg once daily — four 250mg tablets. Should these all be taken together, and at what time of day?
What happens if I miss a dose entirely — should I take it the same day when I remember, or skip until the next day?
Can the tablets be split, crushed, or dissolved if swallowing four tablets is difficult?

About managing common side effects

How will hot flushes and fatigue be managed — are there strategies or medications that help?
Will I need potassium supplementation preventively, or only if levels drop?
If hypertension develops, will my oncologist manage it, or will I be referred back to my primary care doctor or cardiologist?

About bone health — relevant for long-term ADT

Given I am on ADT alongside abiraterone, what is my bone density monitoring plan?
Should I be on a bone-protective agent such as denosumab or zoledronic acid, given the risk of bone loss and bone metastases?

About my specific situation

Does my current medical history — heart disease, diabetes, osteoporosis, prior liver issues — change any aspect of the monitoring or dosing plan?
Are there medications I currently take that interact significantly with abiraterone — particularly those metabolized by CYP2D6, which abiraterone inhibits?

About PSA and response monitoring

How will we track response — PSA trends, imaging, symptoms?
I understand PSA changes don’t always correlate with clinical benefit for individual patients — what signs would indicate the disease is progressing despite treatment?
How often will scans be done?

About the longer road

If abiraterone stops working, what typically comes next — enzalutamide, chemotherapy, PARP inhibitors (if I have relevant mutations), or a clinical trial?
Should I be tested for BRCA1/2 or other DNA repair mutations now, given that PARP inhibitors are approved for mCRPC in patients with these mutations?
Are there patient assistance programs through Janssen/J&J if cost is a concern?

A practical tip: Because abiraterone must always be taken with prednisone and both need to be managed carefully together, it is worth specifically asking whether your oncologist and primary care doctor have a shared plan — particularly for situations like illness (where stress dosing of prednisone may be needed), planned surgery (which requires corticosteroid management), or if you see other doctors who might inadvertently prescribe something that interacts. A written medication card listing the prednisone requirement and the reason for it can be lifesaving if you ever need emergency care from a provider who doesn’t know your full history.

compare with other therapies

Compare abiraterone vs enzalutamide for metastatic castration-resistant prostate cancer

This is one of the most practically important treatment decisions in prostate cancer oncology — and like the pazopanib vs sunitinib comparison, these two drugs have been compared in a direct head-to-head trial (PROTECT — though more limited in scope) alongside a rich body of cross-trial and real-world evidence. They’re the two most widely used oral agents in mCRPC and represent genuinely different mechanisms rather than variations on the same approach.

What they are and how they work

	Abiraterone Acetate (Zytiga)	Enzalutamide (Xtandi)
Drug class	CYP17 inhibitor / androgen biosynthesis inhibitor	Androgen receptor (AR) signaling inhibitor
Mechanism	Blocks production of androgens at all three sources — testes, adrenal glands, and tumor itself	Blocks androgens from binding to and activating the androgen receptor — even if androgens are present
Requires prednisone	Yes — mandatory corticosteroid co-prescription	No — taken as monotherapy
Food restriction	Empty stomach required — up to 10-fold exposure increase with food	Can be taken with or without food
Approved mCRPC	2011 (post-docetaxel); 2012 (chemo-naïve)	2012 (post-docetaxel); 2014 (chemo-naïve)
Manufacturer	Janssen / J&J	Pfizer / Astellas

The mechanistic difference is clinically meaningful: abiraterone reduces the amount of androgen available to drive tumor growth, while enzalutamide blocks the androgen receptor itself — the “lock” rather than the “key.” This distinction has implications for resistance patterns and for which drug might be more useful after the other has stopped working.

Efficacy — no definitive head-to-head superiority

Both drugs have shown nearly identical survival improvements over placebo in their respective pivotal trials across both the post-docetaxel and chemo-naïve mCRPC settings. The PROSPER and ARAMIS trials (testing enzalutamide and darolutamide respectively in non-metastatic CRPC) and the ARCHES trial (enzalutamide in mCSPC) mirror abiraterone’s LATITUDE data — broadly comparable improvements in radiographic progression-free survival and overall survival.

Direct comparison data exists from the HEAT study and a few other retrospective analyses, but no large prospective head-to-head trial has definitively established superiority of either drug over the other for overall survival in mCRPC. Most current treatment guidelines list both as equivalent first-line options in this setting.

The prednisone difference — clinically the most important practical distinction

	Abiraterone	Enzalutamide
Corticosteroid required	Yes — prednisone 5mg (bid for mCRPC; once daily for mCSPC)	No
Adrenal insufficiency risk if stopped	Yes — abrupt prednisone cessation risks adrenal crisis	Not applicable
Stress dosing considerations	Yes — illness, surgery require corticosteroid management	Not applicable
Immunosuppression concerns	Present — chronic corticosteroid use has cumulative effects	Absent
Diabetes / glucose management	More complex — corticosteroids raise blood sugar	Less of a corticosteroid concern

For patients with diabetes, poorly controlled blood sugar, a history of steroid-related complications (cataracts, osteoporosis, peptic ulcer), or anyone who travels frequently or has limited access to emergency care, enzalutamide’s corticosteroid-free profile is a meaningful practical advantage. For patients where the anti-inflammatory effect of prednisone might be additionally beneficial (bone pain, for example), abiraterone’s mandatory corticosteroid may be a relative advantage.

Side effect profiles — different emphasis areas

Side effect	Abiraterone	Enzalutamide
Hypertension	Common (~37%)	Less prominent
Hypokalemia	Common (~20%)	Less common
Fluid retention / edema	Common	Less common
Fatigue	Common	Common — often cited as more pronounced
Seizure risk	Not a concern	Present (~0.5%) — relevant for patients with seizure history
Falls and fractures	Present (ADT-related)	More pronounced — dizziness and falls are a notable concern in older patients
Cognitive effects / mental fog	Less prominent	More commonly reported — particularly in older patients
Hot flushes	Present	Present
Hepatotoxicity	Present — monitoring required	Present but less prominent
Food interaction	Significant — empty stomach required	None

Enzalutamide’s seizure risk and cognitive/fall risk profile in older patients is clinically significant — particularly for men over 75 or those with pre-existing neurological conditions, prior seizures, or who live alone. This side-effect difference often tips the decision toward abiraterone in frailer, older patients.

Sequencing — what happens when one stops working

This is where the mechanistic difference matters most. Because abiraterone and enzalutamide both target the androgen signaling axis — just at different points — there is evidence of significant cross-resistance between them. A tumor that has evolved resistance to abiraterone often has resistance mechanisms (AR amplification, AR splice variants like AR-V7) that also confer resistance to enzalutamide, and vice versa.

The practical implication is that switching between abiraterone and enzalutamide sequentially after one has failed tends to yield modest benefit in most patients — response rates to the second drug after the first has failed are considerably lower than first-line response rates. This is why, once one has been used and has stopped working, the conversation typically moves toward chemotherapy (docetaxel or cabazitaxel) or PARP inhibitors (for BRCA-mutated disease) rather than simply switching to the other drug in the pair.

Where each tends to be preferred in practice

Favor abiraterone when:

Patient has a prior seizure history or high seizure risk
Significant fall or dizziness risk (enzalutamide’s neurological effects are more concerning)
Cognitive concerns are paramount
The anti-inflammatory benefit of prednisone is additionally useful
Patient is well-controlled diabetic (paradoxically — enzalutamide’s effect on blood sugar is less, but abiraterone may be preferred when the diabetes management team is already expert in corticosteroid management)

Favor enzalutamide when:

Patient has diabetes or poorly controlled blood sugar (no corticosteroid)
History of steroid complications (peptic ulcer, cataracts, osteoporosis exacerbation)
Complex medication regimen where adding prednisone and managing adrenal issues is burdensome
Patient travels frequently or has limited access to emergency care (adrenal crisis risk from abrupt prednisone cessation)
The food restriction of abiraterone is genuinely difficult to adhere to

The broader landscape — where these fit now

Both abiraterone and enzalutamide are increasingly being used earlier — in the castration-sensitive setting alongside ADT (abiraterone via LATITUDE, enzalutamide via ARCHES/ENZAMET) — rather than being reserved for the castration-resistant stage. This means some patients will already have received one of these drugs before reaching the mCRPC decision point, which significantly changes the treatment choice at that stage (since using the same agent again or the cross-resistant partner yields much less benefit than first-line use).

PARP inhibitor combinations and other novel approaches are also changing the landscape for specific molecular subtypes — making genetic testing for BRCA1/2, ATM, and other homologous recombination repair genes a relevant parallel conversation for many patients at this stage.

Bottom line

Abiraterone and enzalutamide are therapeutically equivalent in efficacy for mCRPC — the choice between them is almost entirely driven by side-effect profile, comorbidities, and practical adherence factors. The prednisone requirement distinguishes abiraterone most sharply; the seizure, fall, and cognitive risk distinguishes enzalutamide. Both are appropriate first-line choices, and the selection should be individualized against the patient’s specific health profile — particularly relevant for the large proportion of prostate cancer patients who are older and have multiple comorbidities alongside their cancer.

How does testing work

Why must abiraterone always be taken with prednisone and on an empty stomach?

These are two separate but equally important pharmacological reasons — one about mechanism and one about absorption chemistry. Understanding both helps explain why these rules are genuinely non-negotiable rather than cautious overcaution.

Part 1: Why prednisone is mandatory — the mineralocorticoid excess problem

Abiraterone works by blocking CYP17 — an enzyme required for androgen biosynthesis. CYP17 sits at a critical branch point in the steroid hormone production pathway, and blocking it doesn’t just stop androgen production. It also causes a compensatory upstream buildup of steroid precursors that get shunted into an alternative pathway — specifically the mineralocorticoid pathway.

The result is a secondary surge in mineralocorticoids — particularly aldosterone and its precursors — which act on the kidneys to retain sodium and water while excreting potassium. This produces the clinical triad of:

Hypertension — from sodium and water retention increasing blood volume
Hypokalemia — from potassium being lost in urine
Fluid retention / edema — from excess sodium accumulation in tissues

This isn’t a side effect in the traditional sense — it’s a direct, predictable, mechanistic consequence of blocking CYP17, and it happens in essentially all patients to varying degrees.

Prednisone counters this through two mechanisms simultaneously. First, as a glucocorticoid, it provides negative feedback to the adrenal axis — reducing the compensatory drive that is pushing mineralocorticoid precursors to accumulate. Second, it occupies the glucocorticoid receptor in a way that partially competes with some of the excess mineralocorticoid signaling. The combined effect is that mineralocorticoid excess is substantially suppressed when prednisone is present alongside abiraterone.

Without prednisone, mineralocorticoid excess becomes severe and unmanageable — dangerous hypertension, critically low potassium levels, and significant fluid overload can develop. This is why abiraterone was specifically designed and approved as a combination regimen from the outset, not as a drug that optionally pairs with a corticosteroid.

The adrenal insufficiency risk of stopping prednisone abruptly

There is a second reason the prednisone requirement is non-negotiable beyond managing mineralocorticoid excess. Because abiraterone suppresses the entire adrenal steroid synthesis pathway — including cortisol production — patients on abiraterone have reduced adrenal reserve. Their adrenal glands are partially suppressed and cannot mount a normal cortisol stress response.

The prednisone provides exogenous glucocorticoid replacement to compensate for this suppressed endogenous cortisol production. If prednisone is stopped abruptly — for any reason, including running out of prescription, feeling unwell, or a decision by another doctor who isn’t aware of the full picture — the patient may develop adrenal insufficiency. This is a potentially life-threatening condition characterized by:

Severe fatigue and weakness
Nausea, vomiting, and abdominal pain
Low blood pressure and dizziness
Confusion or altered consciousness in severe cases

This is why the emergency advice on abiraterone always includes: never stop prednisone without medical guidance, and ensure any emergency treating physician knows you are on a corticosteroid that cannot simply be discontinued.

Part 2: Why empty stomach — the absorption amplification problem

Abiraterone is a highly lipophilic (fat-soluble) molecule. Like several other oral targeted therapies we’ve discussed in this conversation, its absorption depends on the stomach environment — but abiraterone’s food interaction is more extreme than almost any other drug in this series.

Studies of abiraterone pharmacokinetics showed that the area under the concentration curve (AUC — a measure of total drug exposure) increases dramatically when taken with food:

A low-fat meal increases abiraterone exposure approximately 5-fold compared to fasting
A high-fat meal increases exposure approximately 10-fold compared to fasting

This is one of the largest food-drug absorption interactions known in oral oncology. The mechanism involves bile salt release triggered by food consumption, which dramatically improves the solubility and absorption of lipophilic compounds like abiraterone in the small intestine.

Why this creates a problem rather than an advantage

Instinctively, higher drug exposure might seem beneficial — more drug absorbed should mean more efficacy. But the dose of abiraterone (1,000mg) was specifically calibrated and validated for the fasted state. Clinical trials established both the therapeutic effect and the safety profile at that exposure level.

When taken with food — particularly a high-fat meal — the resulting 5–10x increase in exposure produces unpredictably high drug concentrations that fall outside the tested safety range and significantly increase the risk and severity of side effects, particularly:

Mineralocorticoid excess effects (worsened hypertension, hypokalemia)
Hepatotoxicity risk
General toxicity from suprapherapeutic drug levels

The problem is compounded by variability — if a patient sometimes takes it fasted and sometimes with food, their drug levels swing unpredictably between normal and toxic ranges, making both dosing optimization and side-effect management extremely difficult.

A newer formulation addresses part of this problem

It’s worth knowing that a newer formulation of abiraterone — abiraterone acetate micronized (Yonsa) — was specifically developed to reduce the food effect. By creating much smaller drug particles with greater surface area, Yonsa achieves adequate exposure at a lower dose (500mg rather than 1,000mg) and can be taken with food. Where available, this formulation simplifies the administration requirements considerably.

The 250mg tablet formulation (including Abiraxeen and similar regional brands) corresponds to the original formulation requiring empty-stomach administration — which is why this rule applies to the tablets you’re taking.

The practical takeaway

These two rules — always with prednisone, always on empty stomach — aren’t arbitrary prescribing conventions. They’re direct consequences of abiraterone’s mechanism and its absorption chemistry. The prednisone prevents a mechanistically unavoidable hormonal cascade from becoming dangerous, and provides adrenal support that the suppressed adrenal axis cannot self-supply. The empty stomach rule prevents drug levels from spiking into a range that was never tested and carries meaningful toxicity risk.

Both are genuinely non-negotiable in a way that few drug administration rules are — and both are worth explicitly confirming as understood with your oncologist before the first dose, rather than learning about their importance after a complication occurs.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.